Clinical Trial Update: A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice

View source ↗

Summary

A completed clinical study evaluating the impact of using NovoPen 6 for administration of Tresiba (insulin degludec) and Fiasp (insulin aspart) on blood sugar i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)
• Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 1 | Status: COMPLETED